Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright started coverage on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a report released on Wednesday morning, MarketBeat.com reports. The firm issued a buy rating and a $12.00 target price on the stock.

Several other research firms also recently commented on ARTV. Needham & Company LLC reduced their price target on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 15th. Wedbush restated an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday, March 25th. Finally, Cantor Fitzgerald cut their price objective on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $17.80.

Artiva Biotherapeutics Stock Performance

Shares of ARTV stock opened at $1.96 on Wednesday. The company has a 50 day moving average price of $2.15 and a 200 day moving average price of $5.41. Artiva Biotherapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.15). On average, equities analysts predict that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several hedge funds have recently modified their holdings of ARTV. Wells Fargo & Company MN lifted its holdings in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after acquiring an additional 3,361 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Artiva Biotherapeutics by 262.1% during the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock worth $100,000 after acquiring an additional 7,151 shares during the period. Nuveen LLC purchased a new position in shares of Artiva Biotherapeutics during the 1st quarter worth about $144,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Artiva Biotherapeutics by 26.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company’s stock worth $165,000 after acquiring an additional 11,355 shares during the period. Finally, Deutsche Bank AG purchased a new position in shares of Artiva Biotherapeutics during the 4th quarter worth about $216,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.